Clinical Trials

150 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03446547 2026-04-14

ASTEROID

106 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06141070 2026-04-14

ANDROMEDA

Phase 3 Recruiting

240 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05805631 2026-03-24

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

23 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

GastrointestinalGenitourinaryThoracic

300 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

NCT07192926 2026-02-20

SARCO-CTI

Completed

131 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT07400575 2026-02-10

NSCLC SCLC

Not yet recruiting

350 enrolled

Phase 2 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

NCT06370416 2026-01-28

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

41 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05348668 2026-01-07

Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer

78 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06195527 2026-01-06

PEMBRO-K

75 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07320105 2026-01-06

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

Phase 4 Recruiting

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05277844 2025-09-10

TARGET-01

106 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05278052 2025-09-10

TARGET-02

Phase 3 Recruiting

190 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07131163 2025-08-20

NoSurgery

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06709859 2025-07-17

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Carcinoma, Non-Small-Cell Lung

NCT07050043 2025-07-03

LEDANG

Phase 3 Recruiting

123 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung

NCT03093688 2025-07-02

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Phase 1/2 Recruiting

40 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT07039994 2025-06-26

AIRPAL

200 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06971406 2025-05-14

FLAME-1

100 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06959173 2025-05-06

Organoid-guided Personalized Treatment of Pleural Effusion

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

NCT06926803 2025-04-15

A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases

Active not recruiting

500 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06900283 2025-04-03

FACT-L_Pred

Active not recruiting

320 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

60 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06854939 2025-03-03

MRDSEEKER

Not yet recruiting

350 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT06786208 2025-01-22

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Not yet recruiting

55 enrolled

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06760676 2025-01-07

A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

90 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms

NCT05212103 2024-12-04

CANSI

Enrolling by invitation

DermatologicOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Leukemia, Myeloid, Acute

NCT06679712 2024-11-07

5ALA-TBPDT

Phase NA Not yet recruiting

6 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06249854 2024-10-01

Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

70 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06618391 2024-10-01

Local Injection and Systemic Therapy in the Treatment of NSCLC.

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05269485 2024-06-25

Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Phase 1/2 Recruiting

36 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06454890 2024-06-12

Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

50 enrolled

Phase EARLY_PHASE1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06436885 2024-05-31

An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer

39 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05878028 2024-05-23

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06406608 2024-05-09

Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02991924 2024-04-04

Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer

Active not recruiting

600 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

132 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT05377658 2024-02-21

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

43 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06188650 2024-01-03

The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study

Carcinoma, Non-Small-Cell Lung

NCT05421936 2023-11-22

UNICORN

Suspended

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04074993 2023-09-28

Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05675033 2023-01-09

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

50 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT01003964 2022-04-12

Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV

289 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01156545 2022-04-06

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

68 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01470716 2022-04-06

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03808480 2022-04-06

Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

22 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05252091 2022-02-23

An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC

Carcinoma, Non-Small-Cell Lung

NCT02938624 2021-12-14

MK3475-223

Phase 1 Completed

28 enrolled